NewsBenzingaQuanterix conferma una guidance sulle vendite per l’esercizio 2026 di 142,000 milioni di dollari-146,000 milioni di dollari rispetto ai 143,357 milioni di dollari stimati Quanterix conferma una guidance sulle vendite per l’esercizio 2026 di 142,000 milioni di dollari-146,000 milioni di dollari rispetto ai 143,357 milioni di dollari stimati Benzinga 2026.11.18 13:36 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform Quanterix Affirms FY2026 Sales Guidance of $142.000M-$146.000M vs $143.357M Est
OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform